

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Renal Advantage Inc.		06/03/2010	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Deutsche Bank Trust Company Americas, as collateral agent		
<b>Street Address:</b>	60 Wall Street		
<b>City:</b>	New York		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10005		
<b>Entity Type:</b>	CORPORATION: NEW YORK		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
Registration Number:	3654627	RAI	
Registration Number:	2298508	RENALAB	
Serial Number:	76701238	RENALAB INSIGHT	
<b>CORRESPONDENCE DATA</b>			
Fax Number:	(212)354-8113		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	2128198200		
Email:	fcutajar@whitecase.com		
Correspondent Name:	White & Case LLP		
Address Line 1:	1155 Avenue of the Americas		
Address Line 2:	Patents & Trademarks		
Address Line 4:	New York, NEW YORK 10036		
ATTORNEY DOCKET NUMBER:	1111779-2036		
NAME OF SUBMITTER:	Frances B. Cutajar		

OP \$90.00 3654627

**900164629**

**TRADEMARK  
 REEL: 004224 FRAME: 0715**

Signature:	/Frances B. Cutajar/
Date:	06/15/2010
Total Attachments: 4 source=DBRenalAdvantageTMSecurityInterest#page1.tif source=DBRenalAdvantageTMSecurityInterest#page2.tif source=DBRenalAdvantageTMSecurityInterest#page3.tif source=DBRenalAdvantageTMSecurityInterest#page4.tif	

GRANT OF SECURITY INTEREST  
IN UNITED STATES TRADEMARKS


FOR GOOD AND VALUABLE CONSIDERATION, receipt and sufficiency of which are hereby acknowledged, Renal Advantage Inc., a Delaware corporation (the "Grantor") with principal offices at 115 East Park Drive, Suite 300, Brentwood, TN 37027, hereby grants to Deutsche Bank Trust Company Americas, as Collateral Agent, with principal offices at 60 Wall Street, New York, New York 10005, (the "Grantee"), a continuing security interest in (i) all of the Grantor's right, title and interest in, to and under to the United States trademarks, trademark registrations and trademark applications (the "Marks") set forth on Schedule A attached hereto, (ii) all Proceeds (as such term is defined in the Guarantee and Collateral Agreement referred to below) and products of the Marks, (iii) the goodwill of the businesses with which the Marks are associated and (iv) all causes of action arising prior to or after the date hereof for infringement of any of the Marks or unfair competition regarding the same.

THIS GRANT, dated June 3, 2010, is made to secure the satisfactory performance and payment of all the Obligations of the Grantor, as such term is defined in the Guarantee and Collateral Agreement among the Grantor, the other assignors from time to time party thereto and the Grantee, dated as of June 3, 2010 (as amended, modified, restated and/or supplemented from time to time, the "Collateral Agreement").

This Grant has been granted in conjunction with the security interest granted to the Grantee under the Collateral Agreement. The rights and remedies of the Grantee with respect to the security interest granted herein are as set forth in the Collateral Agreement, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this Grant are deemed to conflict with the Collateral Agreement, the provisions of the Collateral Agreement shall govern.

IN WITNESS WHEREOF, the undersigned have executed this Grant as of the first date written above.


RENAL ADVANTAGE INC., Grantor

By 

Name: Michael D. Klein

Title: President & Chief Executive Officer

DEUTSCHE BANK TRUST COMPANY  
AMERICAS, as Collateral Agent and Grantee

By   
Name: Erin Morrissey  
Title: Vice President

By   
Name: Marguerite Sutton  
Title: Director

SCHEDULE A

<u>MARK</u>	<u>REG. NO./SERIAL NO.</u>	<u>REG. DATE/FILING DATE</u>
RAI	3,654,627	July 14, 2009
RenaLab	2,298,508	December 7, 1999
RenaLab Insight	76/701,238	January 19, 2010